Back
Credit Acceptance 10K Form
Buy
52
CACC
Credit Acceptance
Last Price:
$531.47
Seasonality Move:
5.09%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-04-30 | 10Q | CACC/Credit Acceptance Quarterly |
2024-02-12 | 10K | CACC/Credit Acceptance Annual |
2023-10-30 | 10Q | CACC/Credit Acceptance Quarterly |
2023-08-01 | 10Q | CACC/Credit Acceptance Quarterly |
2023-05-01 | 10Q | CACC/Credit Acceptance Quarterly |
2023-02-10 | 10K | CACC/Credit Acceptance Annual |
Receive CACC News And Ratings
See the #1 stock for the next 7 days that we like better than CACC
CACC Financial Statistics
Sales & Book Value
Annual Sales: | $2.1B |
---|---|
Cash Flow: | $345.9M |
Price / Cash Flow: | 5.59 |
Annual Sales: | $145.63 |
Price / Book: | 3.6 |
Profitability
EPS (TTM): | 23.44000 |
---|---|
Net Income (TTM): | $289.9M |
Gross Margin: | $1.3B |
Return on Equity: | 17.43% |
Return on Assets: | 3.36% |
Credit Acceptance Earnings Forecast
Key Credit Acceptance Financial Ratios
-
The Gross Profit Margin over the past 21 years for CACC is 62.41%.
-
The Selling, General & Administrative Expenses for CACC have been equal to 9.01% of Gross Profit Margin.
-
The Interest Expense is 29.90% of Operating Income.
-
The Net Earning history of CACC is 11.62% of Total Revenues.
-
Per Share Earnings over the last 33 years have been positive in 24 years.
Credit Acceptance Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Consumer Finance |
Sector: | Financials |
Current Symbol: | CACC |
CUSIP: | 225310 |
Website: | creditacceptance.com |
Debt
Debt-to-Equity Ratio: | 3.92 |
---|---|
Current Ratio: | 17.5 |
Quick Ratio: | 16.34 |
Price-to-Earnings
Trailing P/E Ratio: | 26.69 |
---|---|
Forward P/E Ratio: | 11.57 |
CACC Technical Analysis vs Fundamental Analysis
Buy
52
Credit Acceptance (CACC)
is a Buy
Is Credit Acceptance a Buy or a Sell?
-
Credit Acceptance stock is rated a BuyThe current Credit Acceptance [CACC] share price is $531.95. The Score for CACC is 52, which is 4% above its historic median score of 50, and infers lower risk than normal.